Benign ovarian cysts ‘common side effect’ of adjunctive transplant therapy
Drugs in the mTOR inhibitor class have been assessed in a meta-analysis
Ovarian cyst development is a common side effect of treatment with a class of drugs used as prophylactic immunosuppressants after organ transplants, Italian researchers say.
The mTOR (mammalian target of rapamycin) inhibitor therapy class includes sirolimus, tacrolimus, everolimus and temsirolimus, which are approved for use in Australia.
The researchers searched the literature for evidence on ovarian cyst development during mTOR inhibitor treatment, finding seven eligible studies including a total of 406 women.
In the different studies, the incidences of ovarian cysts with use of the drug class ranged from less than 10% to more than 50%.
